In the sedentary era, weight gain is becoming a serious preventable risk factor for increased body mass index which strongly correlates with enhanced cancer threat.
As reported cancers of endometrial, oesophageal adenocarcinoma, colorectal, postmenopausal breast, prostate & renal are caused due to surplus weight.
The body’s lean shape is regulated by the delicate balance between adipocytes & immune cells. Chronic nutrient overload leads to adipocyte hypertrophy, mitochondrial dysfunction, increased oxidative & endoplasmic reticulum stress, proinflammatory signaling, adipokine secretion & cell death. Collectively instigate enhanced secretion of proinflammatory factors, dysregulated systemic metabolism, tumor growth, metastasis & progression.
• Alteration in an adipose stromovascular fraction.
• Reduction in anti-inflammatory Treg & TH2 cells.
• Increase in proinflammatory TH1 & CD8+T cells.
• Variation in M2 to M1 macrophages.
1. Adipokines - Weight gain alters the interaction between adipocytes and adipokine production.
2. Adiponectin- Obesity triggers adiponectin reduction & causes a mutation in adiponectin receptors (ADIPOR1 & ADIPR2).
3. Leptin -Excessive weight facilitates leptin resistance & hyperlipidemia, and enables cell proliferation, migration, invasion responses, and tumor development.
4. Estrogen- Increased weight fosters adipose-derived aromatase activity, estrogen production, systemic estrogen bioavailability, adipose-derived proinflammatory factors (IL-1β, IL-6, prostaglandin E2, and TNFα), liver-derived insulin growth factor 1 (IGF-1).
5. IL-6 and TNFα- Obesity-induced excess IL- and TNFα levels encourage cellular transformation, proliferation, invasion, angiogenesis, metastasis, cancer cell proliferation, survival & angiogenesis.
6. IL-1β- Heavy weight increases free fatty acid, cholesterol, blood sugar, and free radical levels stimulating tumor expression of IL-1β, NOD-like receptor family, pyrin domain containing 3 (NLRP3) & inflammasome activity.
7. Osteopenia-Neoplastic transformation, cancer cell survival & metastasis progression enhances due to obesity-driven osteopenia phosphoprotein.
8. YKL-40- Excessive obesity with diabetes generates YKL-40, cancer cell proliferation, angiogenesis, and extracellular matrix remodeling.
9. PAI-1- Advancing obesity increases PAI-1 (serine protease inhibitor), cancer cell invasion, metastasis & tumors.
10. Endotrophic -Increased adipose tissue promotes endotrophic production, and activates TGF-β signaling, tumor cell growth & metastasis.
• Central obesity causes insulin resistance, dyslipidemia, hyperglycemia & metabolic dysfunction.
• Visceral adipose tissue aggravates the abdominal cavity’s momentum & produces more pro-inflammatory factors.
Weight loss decreases infiltrating macrophages in adipose tissue inflammation, systemic complications of proinflammatory adipokines, obesity-linked pathologies & delays carcinogenesis. Dietary restriction-motivated weight loss reduces colorectal inflammation, decreases rectosigmoid expression of multiple proinflammatory cytokines and markers of T -cell, macrophage accumulation & attenuates cancer pathways (FOS, JUN, STAT3, and NF-κB expression).
Visible weight loss reduces cancer risk, diminishes adipose-related inflammatory mechanisms, and regulates tumor development & progression. Reduction and control of cancer risk demand a better understanding of cellular & molecular mechanisms behind obesity-induced inflammation, the proactive invention of early diagnosis biomarkers & accessible effective cancer therapy.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
Black women have a higher risk of dying from all types of breast cancer, meta-analysis reveals
2.
Every cancer is different because of how evolution causes drug resistance and why various cancers require various treatments.
3.
Preschoolers With Cancer Have Poor Motor Skills
4.
When it comes to obesity-related cancers, where you shop for food matters
5.
Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC
1.
Unleashing the Inner Predator: Reprogramming Macrophages to Conquer Cancer Immunotherapy
2.
From Bench to Bedside: The New Era of Lymphoma Treatment and Education
3.
Red Cell Deformability as a Target in Critical Illness
4.
Cerebrospinal Fluid Metabolite Biomarkers in Central Nervous System Tumor Monitoring: A New Frontier
5.
Tumor Mutation Signatures From Replication Stress: Mechanisms, Clinical Implications, and Emerging Therapeutic Insights
1.
International Conference on Cancer Nursing and Rehabilitation Strategies
2.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
3.
International Conference on Innovations in Critical Care for Oncology and Cardiology
4.
International Symposium on Oncology, Cardiology and Critical Care Innovations
5.
International Conference on Cancer Nursing and Hematology Support
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
2.
Signs and Symptoms of Leukemia
3.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
4.
From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD
5.
Navigating the Complexities of Ph Negative ALL - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation